Issue 39

EXCLUSIVE: Field Trip’s Co-founder and Executive Chairman Ronan Levy on Investor Opportunities Following Nasdaq Listing

Field Trip will join the Nasdaq exchange on 29 July and become the first psychedelic company to list on Nasdaq’s Global Select Market, having met the stringent financial requirements for the stock exchange’s top tier.

The eagerly anticipated uplisting is the latest in a series of significant company announcements. In February, Field Trip signed a bought deal with investment bank Bloom Burton Securities, and in March raised US$95m in a single funding round. The organisation’s financiers are predominantly investment banks and hedge funds, but what does the support of institutional investors mean for the recognition and regulation of psychedelic medicine?

Read More

CYBIN TO LIST ON NYSE’S SMALL CAP MARKET TO FINANCE EXPANSION

The company studying sublingual formulation of psilocybin, with a market cap of US$446m, has gained conditional approval to list on the New York Stock Exchange’s small cap equity market.

Read More

THE TIMES: PSYCHEDELIC FIRMS TAKE A TRIP OVER THE ATLANTIC IN SEARCH OF FUNDS

UK companies are joining North American stock exchanges to tap foreign investors. Compass Pathways listed on the Nasdaq, with Awakn and Small Pharma joining the Toronto Stock Exchange.

Read More

BUSINESS AND INVESTMENT

Field Trip to become fifth psychedelics company to list on Nasdaq.

Red Light Holland provides update on CA$30m cash position.

Levitee to acquire ACT Medical, BlockMD and Canadian clinics.

Klarisana opens a ketamine therapy clinic in Centennial, Colorado.

Mydecine patents MDMA-derivative.

Psyched Wellness partners with MB Memel Goods or tests on amanita muscaria derivative.

Havn Life signs agreement with P.A. Benjamin Manufacturing Company.

PsiloThera creates crowdfunding campaign.

Small Pharma creates psychedelic therapy training programme.

Awakn Life Sciences lists on OTC markets.

PharmaTher patents ketamine formulation.

Silo Wellness files drug delivery patent.

Cybin launches overnight market offering.

Ketamine One applies for controlled substance dealer’s license.

Tryp appoints Robin Carhart-Harris as Scientific Advisory Board Chairman and Daniel Clauw to the board.

Kaiyon Biotech appoints Dr DaeHee Lee as CEO.

Diamond Therapeutics appoints David Brown as VP of Pharmaceutical Development.

PharmaDrug changes CSE ticker symbol to PHRX.

Optimi Health enlists John Simon to facilitate psychedelic research submissions.

RESEARCH AND SCIENCE

MindMed starts Phase 1 clinical trial of intravenous DMT.

Braxia Scientific’s CEO and CMO receive government grant to study ketamine.

BetterLife Pharma receives Mitacs funding for anxiety and depression research.

Ketamine One to measure brain function in injured veterans.

Psychedelic trips could soon be part of therapy – here’s what those sessions will look like.

Clinical research into psychedelic medicine flourished for decades before criminalisation.

New model helps map the individual variations of mental illness.

Doctors treating depression see potential in ketamine.

REGULATION AND LEGISLATION

US Congress rejects proposed amendment to promote psychedelic research.

Medical researchers give psilocybin positive recommendation to Oregon Health Authority.

New poll finds majority of Canadians support legal access to psilocybin therapy.

Health Canada dragging feet on approving magic mushrooms for therapeutic use, patients and advocates say.

Gabon’s government is tripping for a psychedelic plant.

Partner with us